In conclusion, our study underscores the potential utility of cytokine profiling, particularly IL-2, sPD-L1, and IL-23 into clinical practice to improve patient selection and personalize immunotherapy strategies in advanced NSCLC. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.